RxDoctor Payments Data

William Baker, DO

Family Medicine · Las Cruces, NMNPI 1215913447

Payments from drug & device makers

$1,167in general payments, 2019–2025

Across 50 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$404
  • Novo Nordisk$176
  • Globus Medical$146
  • AbbVie$127
  • Merck$79
  • GSK$62
  • plus $172 from 4 others

What the payments were for

  • Food & beverage$1,167100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca10$404
Novo Nordisk16$176
Globus Medical1$146
AbbVie(2 entities)8$127
Merck5$79
GSK3$62
Stryker1$61
Lilly USA, LLC3$48
Abbott2$44
Ironwood Pharmaceuticals, Inc1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,167 in reported general payments places this provider in the 80th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$318,533
Medicare patients
574
Services billed
2,960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$193,420
JardianceEmpagliflozin96$85,620
XareltoRivaroxaban44$61,045
EliquisApixaban62$58,633
RybelsusSemaglutide32$41,495
FarxigaDapagliflozin Propanediol32$33,949
JanuviaSitagliptin Phosphate21$30,773
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$29,872
MyrbetriqMirabegron35$29,377
MounjaroTirzepatide16$23,351
JanumetSitagliptin Phos/Metformin Hcl33$22,560
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$18,486
LinzessLinaclotide18$18,060
Tresiba Flextouch U-200Insulin Degludec15$9,999
Levothyroxine Sodium690$8,690

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$176$234,914166 claims
MerckJanuvia, Janumet$79$53,33354 claims
AstraZenecaFarxiga, Breztri Aerosphere$404$52,43562 claims
GSKTrelegy Ellipta$62$29,87244 claims
Lilly USA, LLCMounjaro$48$23,35116 claims
AbbVieLinzess, Synthroid$127$21,509124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →